Skip to main content
editorial
. 2010 Jun 28;16(24):2963–2970. doi: 10.3748/wjg.v16.i24.2963

Figure 3.

Figure 3

Kaplan Meier curve demonstrating time to tumor progression in patients treated with octreotide long-acting repeatable (LAR) vs placebo[69]. Log-rank test stratified by functional activity: P = 0.000072, HR = 0.34 (95% CI: 0.20-0.59).